Massachusetts Financial Services Co. MA Sells 2,491,865 Shares of Boston Scientific Corporation $BSX

Massachusetts Financial Services Co. MA trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 19.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 10,367,293 shares of the medical equipment provider’s stock after selling 2,491,865 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Boston Scientific were worth $1,012,159,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC raised its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Steph & Co. purchased a new stake in Boston Scientific during the third quarter valued at about $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the third quarter worth about $25,000. Finally, Kilter Group LLC bought a new stake in shares of Boston Scientific in the second quarter valued at approximately $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. The Goldman Sachs Group reissued a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a report on Friday, January 9th. Wells Fargo & Company lifted their target price on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Finally, Royal Bank Of Canada increased their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $123.89.

Insider Buying and Selling

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 93,095 shares of company stock worth $9,305,450. Corporate insiders own 0.50% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Boston Scientific Stock Down 2.1%

Shares of NYSE BSX opened at $88.13 on Friday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The business has a 50-day moving average of $96.90 and a 200-day moving average of $100.29. The firm has a market capitalization of $130.65 billion, a price-to-earnings ratio of 47.13, a PEG ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the business posted $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.